Navigation Links
Study identifies causes of bone loss in breast cancer survivors
Date:11/19/2008

MAYWOOD -- Osteoporosis is a growing concern among breast cancer survivors and their doctors, because certain cancer drugs can cause bone loss.

But a new study has found that cancer drugs aren't the only culprits. Among 64 breast cancer patients referred to a bone health clinic, 78 percent had at least one other cause of bone loss, including vitamin D deficiency, excessive calcium excretion in urine and an overactive parathyroid gland.

"Doctors evaluating breast cancer patients for possible bone loss should look further than cancer drugs," said Dr. Pauline Camacho, lead author of the study in the Journal of Clinical Oncology. Camacho is an associate professor in the department of medicine, division of endocrinology and metabolism, Loyola University Chicago Stritch School of Medicine.

A co-author of the study, Dr. Kathy Albain, said breast cancer survivors "are just like the normal population as they age in that bone loss can be due to many treatable causes." Albain is a professor in the Department of Medicine, division of hematology/oncology at Stritch.

Previous studies have found that chemotherapy drugs can cause bone loss. Studies also have found that a class of breast cancer drugs called aromatase inhibitors can decrease bone mineral density and increase the risk of fractures in postmenopausal women. Aromatase inhibitors decrease the body's production of estrogen. While estrogen feeds cancer, it also protects against osteoporosis. Aromatase inhibitors include letrozole (trade name, Femara), anastrazole (Arimidex) and exemestane (Aromasin).

Researchers reviewed charts of 238 consecutive postmenopausal patients who had osteoporosis or osteopenia and were referred to the Loyola's Osteoporosis and Metabolic Bone Disease Center from 2000 to 2006. (Osteopenia is lower than normal bone mineral density, but not low enough to be classified as osteoporosis.) The patients included 64 women with breast cancer referre
'/>"/>

Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System
Source:Eurekalert

Page: 1 2

Related medicine news :

1. New Study by BioTrends Highlights Practice Management Shifts Among Canadian Nephrologists
2. Study Suggests Need for More Aggressive Outpatient Monitoring of Patients Hearts When Cause of Stroke is Unclear
3. Rutgers researchers study cites media violence as critical risk factor for aggression
4. Brigham and Womens Researchers Partner with Vocantas to use CallAssure in Clinical Research Study
5. Analyst Available to Comment on New JUPITER Study That Shows AstraZenecas Crestor Significantly Reduces CV Risk
6. New Study Finds CO2 Ablative Fractional Resurfacing Safe And Effective For Deep Acne Scarring
7. Study investigates Gore-tex-type device to stop strokes and mini-strokes
8. The smart way to study
9. Case Western Reserve University study examines working couples retirement patterns
10. Surgical study highlights pros and cons of gastric bypass surgery for severe obesity
11. Hepatitis C Therapeutic DNA Vaccine Delivered by Inovio Biomedical's Electroporation Technology Reduces Viral Load by Up to 99.7% : Clinical Data Presented at Annual Scientific Meeting of the American Association for the Study of Liver Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... 30, 2015 , ... Between 2012 and 2014 HIV infection rates rose from ... on June 17th. Those untreated heroin use disorders share their needles and spread the ... needles throughout the community. Ultimately Florida’s HIV infection rates have bolstered to 23 percent ...
(Date:7/30/2015)... Dana Point, CA (PRWEB) , ... July 30, 2015 , ... ... the highest honors available, including the very rare “no recommendations.” No recommendations means CARF ... full compliance; this is a notation that less than 3% of all facilities receive. ...
(Date:7/30/2015)... Alexandria, VA (PRWEB) , ... July 30, 2015 ... ... applauds Drug Enforcement Administration (DEA) Acting Administrator Chuck Rosenberg’s announcement of the reinstitution ... been scheduled for Saturday, September 26, 2015 from 10:00 AM to 2:00 PM ...
(Date:7/30/2015)... ... July 30, 2015 , ... The Tisch ... Institute Designation , The Tisch Cancer Institute (TCI) at the Icahn School of ... center. TCI joins an elite group of 69 cancer institutions nationwide that have ...
(Date:7/30/2015)... PA (PRWEB) , ... July 30, 2015 , ... ... inventor from Texas, has designed a personal-care device that makes it easy to apply ... Buddy” could eliminate the need for assistance when applying lotion or medication to the ...
Breaking Medicine News(10 mins):Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3Health News:Ocean Hills Recovery Receives Accreditation from CARF International 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6Health News:InventHelp® Client Patents “My Back Buddy” – Device Could Apply Lotion to Hard-to-Reach Areas Easily 2
... for the Fourth Quarter was $ 0.28 per share ... the Year ... End, LANCASTER, Pa., Oct. 11 Herley Industries,Inc. (Nasdaq: HRLY ) today reported ... income during the fourth quarter of 2007 was $3.8 million or $.28,per share, as compared ...
... a simple tool that can improve the effectiveness of ... result in dramatic improvements in health and safety. , ... with color images of the medication to be taken ... in a patient,s native language if the patient does ...
... Oct. 11 The law firm of Kohn, Swift ... has been,commenced against Pall Corporation ("Pall" or the "Company") ... States District Court for the Eastern,District of New York, ... of all investors who purchased Pall securities between April,20, ...
... Tahoe, CA, October 11, 2007 Cancer researchers have ... after the use of therapies designed to stop the ... cell growth. New research has now detected that androgen-synthesizing ... cancer cells may develop the capacity to produce their ...
... implicated in prostate and breast cancer development may also ... Researchers at the Kimmel Cancer Center at Jefferson in ... normally applies the brakes on a cancer-causing gene ... Though the work is preliminary, the scientists say, the ...
... CHESHIRE, Conn., Oct. 11 Alexion,Pharmaceuticals, Inc. (Nasdaq: ... conference call and audio web cast on Thursday, October ... with the release of its,financial results for the third ... results at 6:30 a.m. ET on Thursday,October 25, 2007. ...
Cached Medicine News:Health News:Herley Reports 4th Quarter and Year-End Results 2Health News:Herley Reports 4th Quarter and Year-End Results 3Health News:Herley Reports 4th Quarter and Year-End Results 4Health News:Herley Reports 4th Quarter and Year-End Results 5Health News:Herley Reports 4th Quarter and Year-End Results 6Health News:Herley Reports 4th Quarter and Year-End Results 7Health News:Herley Reports 4th Quarter and Year-End Results 8Health News:Herley Reports 4th Quarter and Year-End Results 9Health News:Herley Reports 4th Quarter and Year-End Results 10Health News:Herley Reports 4th Quarter and Year-End Results 11Health News:Improving doctor-patient communication yields significant health benefits 2Health News:Improving doctor-patient communication yields significant health benefits 3Health News:Improving doctor-patient communication yields significant health benefits 4Health News:Kohn, Swift & Graf, P.C. Announces Commencement of Lawsuit Against Pall Corporation-PLL 2Health News:Kohn, Swift & Graf, P.C. Announces Commencement of Lawsuit Against Pall Corporation-PLL 3Health News:New research may show why some prostate cancer recurs after treatment 2Health News:New research may show why some prostate cancer recurs after treatment 3Health News:Jefferson scientists find protein may be key in developing deadly form of pancreatic cancer 2
(Date:7/30/2015)...  Medimetriks Pharmaceuticals, Inc. announced today that its ... study for Ozenoxacin, a novel bactericidal non-fluorinated quinolone ... U.S. rights to Ozenoxacin 1% cream.  ... with an emphasis on U.S. patients, involved 412 ... older with a clinical diagnosis of bullous or ...
(Date:7/30/2015)... , July 30, 2015 Vermillion, ... on gynecologic disease, announced today it will ... after the market close on Thursday, August ... call and webcast at 4:30pm Eastern.Conference Call ... at 4:30pm Eastern/1:30pm Pacific  Domestic: ...
(Date:7/30/2015)... , July 30, 2015  Big Cloud Analytics, ... analytics technology, announces it is working with Intel ... for the new Lockheed Martin Healthcare Technology Alliance. ... health information technology providers, medical technology companies and ... and innovation to improve care in rapidly evolving ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 2Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 3
Quantitative determination of Fibrinogen by STA Analyzers (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Determination of Prothrombin Time (PT) by STA Analyzers (ISI~1.3).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
The ALB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of albumin in serum...
The PHOS method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of phosphorus in serum....
Medicine Products: